Freya Biosciences Advances FB301 After Positive Phase 1 Data in Women’s Reproductive Health

New updates have been reported about Freya Biosciences.

Freya Biosciences reported positive topline data from a Phase 1 first-in-human trial of FB301, a defined multi-strain Lactobacillus consortium developed on its Dyscover platform as a potential treatment for IVF-related embryo implantation failure. The randomized, placebo-controlled, double-blind study in 89 healthy women aged 18–45 across three dosing cohorts showed FB301 was safe and well tolerated, with no serious or severe adverse events or treatment discontinuations.

FB301 was administered as a vaginal capsule either once, or once daily for five or ten days, and met all primary and secondary endpoints, including proof-of-concept on vaginal microbiome modulation. Treatment produced significant increases from baseline in key Lactobacillus species, and in women with baseline dysbiosis, FB301 converted microbiomes toward a Lactobacillus-dominant profile across all dosing regimens.

At six months, 50% of participants in the highest-dose group had shifted to a non-dysbiotic profile versus 11.1% on placebo, with statistical analyses confirming significant Lactobacillus gains versus baseline and pooled data supporting a treatment effect over placebo. Management highlighted that the results support the hypothesized mechanism of resolving vaginal dysbiosis and local inflammation, reinforcing FB301’s potential to improve outcomes in women undergoing assisted reproductive technologies.

Freya will now move FB301 into Phase 2 development in women undergoing frozen embryo transfer and in a bacterial vaginosis population to refine dosing strategies. The company has secured FDA IND clearance for a U.S. frozen embryo transfer trial (NCT07453069) and German CTA approval for a bacterial vaginosis optimization study (NCT07481955), positioning FB301 as a Phase 2-ready asset in a large, underserved women’s health market.

Executives see the Phase 1 data as validation of the Dyscover platform, which uses multi-omics and a large biobank to identify microbiome-based interventions addressing immune dysregulation critical to reproductive health. Backed by global life sciences investors, Freya is building a focused pipeline around FB301 and other first-in-class candidates targeting IVF-related failure and preterm birth, with Phase 2 progression likely to be a key value inflection point for the company.